Donepezil
General Information
Donepezil Impurities and Donepezil
Daicel Pharma offers high-quality Donepezil impurities such as Donepezil EP Impurity H and Donepezil Open Ring. They are vital for evaluating the quality, stability, and biological safety of Donepezil. Furthermore, Daicel Pharma specializes in the custom synthesis of Donepezil impurities and ensures their worldwide delivery.
Donepezil [CAS: 120014-06-4] is an oral medicine for Alzheimer’s disease treatment. It is a racemate of equimolar amounts of (R)- and (S)-Donepezil. It reversibly inhibits acetylcholinesterase, primarily aiming to elevate cortical acetylcholine levels in Alzheimer’s therapy.
Donepezil: Use and Commercial Availability
Donepezil, in its hydrochloride form, is a piperidine derivative. It is for treating Alzheimer’s disease. It also treats dementia in mild and moderate forms. Donepezil is marketed under the brand names Aricept and Adlarity.
Donepezil Structure and Mechanism of Action
The chemical name of Donepezil is 2,3-Dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one. The chemical formula for Donepezil is C24H29NO3, and its molecular weight is approximately 379.5g/mol.
Donepezil is a centrally acting, reversible acetylcholinesterase inhibitor that breaks down acetylcholine after its release from the presynapse. It prevents acetylcholine hydrolysis, thereby increasing the availability of acetylcholine at the synapses. Further, it enhances cholinergic transmission.
Donepezil Impurities and Synthesis
During the synthesis1 of Donepezil, precise measures can uphold its purity and potency. Despite these precautions, impurities can occur, affecting the drug’s quality. Advanced purification techniques such as chromatography and crystallization can mitigate impurities, preserving the integrity of Donepezil.
Daicel Pharma offers a comprehensive Certificate of Analysis (CoA) for Donepezil impurities, such as Donepezil EP Impurity H and Donepezil Open Ring. The CoA is from a cGMP-compliant analytical facility and encompasses complete characterization data such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity2. We give additional data, like 13C-DEPT and CHN, on request. Daicel Pharma can also prepare any unidentified Donepezil impurity or degradation product. Furthermore, Daicel Pharma offers highly purified isotope-labeled standards of Donepezil for bioanalytical research and BA/BE studies. We give a complete characterization report upon delivery.
References
FAQ's
References
- Sugimoto, Hachiro; Tsuchiya, Yutaka; Higurashi, Kunizou; Karibe, Norio; Iimura, Yuoichi; Sasaki, Atsushi; Yamanashi, Yoshiharu; Ogura, Hiroo; Araki, Shin, 1,4-Substituted piperidines as acetylcholinesterase inhibitors and their use for the treatment of Alzheimer's disease, EP296560B1, Dec 28, 1988, Eisai Co., Ltd., Japan
- Pappa, Horacio; Farru, Romina; Vilanova, Paula Otano; Palacios, Marcelo; Pizzorno, Maria Teresa, A new HPLC method to determine Donepezil hydrochloride in tablets, Journal of Pharmaceutical and Biomedical Analysis, Volume: 27, Issue: 1-2, Pages: 177-182, 2002, DOI: (10.1016/s0731-7085(01)00499-x)
Frequently Asked Questions
Can Donepezil impurities affect the therapeutic efficacy of the drug?
Some impurities may impact the pharmacological activity of Donepezil, leading to reduced efficacy or adverse effects in patients.
What is the impact of impurities on the stability of Donepezil?
Impurities can affect the stability of Donepezil, leading to a decrease in its shelf life.
How are impurities detected in Donepezil?
Impurities in Donepezil can be detected using various analytical techniques such as HPLC.
How can the formation of impurities be minimized during the synthetic process?
The formation of impurities can be minimized by optimizing the synthesis process, using high-quality raw materials, and maintaining strict quality control measures.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.